Navigation

NEWS RELEASES

Search all of our news releases here.

Search
Generic filters

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

American Gene Technologies Appoints Dr. Jeff Boyle as Chief Science Officer

Jun 21, 2022

Dr. Boyle’s biotech and intellectual property expertise strengthen the team as the company proceeds to next phase of its HIV cure clinical trial American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post… [Read More]

angel

American Gene Technologies Attracts Investment from Ride Wave Ventures

Apr 22, 2022

AGT welcomes additional support of its HIV Cure clinical trial and broad gene therapy development platform American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced today that angel investor Ride Wave Ventures has made its first investment in the company.   Ride… [Read More]

American Gene Technologies Launches “The Cure Chronicles” Video Series

Mar 30, 2022

“The Cure Chronicles” presents thoughtful conversations with people living with HIV, advocates, medical experts, policymakers, and others working toward ending the HIV epidemic. American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, has launched a video series showcasing compelling HIV community conversations: The… [Read More]

American Gene Technologies Applauds the State of Maryland for Supporting Biotech Investment

Mar 2, 2022

Maryland’s Biotechnology Investment Incentive Tax Credit (BIITC) program generates multiple benefits for the state American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, thanks the State of Maryland for its commitment to supporting biotech research through initiatives like the Biotechnology Investment Incentive… [Read More]

American Gene Technologies Advances Closer to Demonstrating a Potential Cure for HIV

Feb 24, 2022

HIV cure clinical trial data shows safety and efficacy of AGT’s gene therapy treatment, the company will begin withdrawing participants from antiretrovirals in Q2 to test potential functional cure American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that the independent… [Read More]

American Gene Technologies’ HIV Clinical Trial Shows Blood Markers of Efficacy in Two More Patients

Feb 2, 2022

Data from a Total of Five Patients Demonstrates Critical Markers of the Company’s HIV Cure Gene & Cell Therapy American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that it has reached another important milestone for its HIV cure program. Five participants… [Read More]

American Gene Technologies Appoints Dr. Drew Palin as Business and Strategy Advisor to the CEO

Jan 5, 2022

Dr. Palin’s expertise in the intersection of business and technology strengthens AGT’s capability to bring patient solutions to the market. American Gene Technologies (AGT) announces the appointment of Dr. Drew Palin as business and strategy advisor to Jeff Galvin, CEO.   “I am excited to have… [Read More]

American Gene Technologies’ HIV Clinical Trial Demonstrates Blood Markers of Efficacy

Dec 21, 2021

Data from the First Three Patients Shows Critical Markers of the HIV Cure Cell Therapy: Engraftment, Persistence, and Function of Infused Cells American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure… [Read More]

American Gene Technologies Passes Major Milestone in Potential HIV Cure Clinical Trial with Third Patient Showing No Serious Adverse Effects (SAEs)

Nov 9, 2021

American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) overseeing the trial of AGT’s HIV gene therapy found no serious adverse events (SAEs) from the treatment for the third patient and voted unanimously to allow AGT’s HIV… [Read More]

American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO

Oct 1, 2021

Dr. Conant, one of the first HIV/AIDS treatment pioneers, strengthens AGT’s capacity to progress toward a functional cure October 01, 2021 13:25 ET | Source:  American Gene Technologies American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and… [Read More]

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media